Redcare Pharmacy N.V. has increased its full-year 2026 revenue guidance for the second time this year, citing continued strong momentum in prescription (Rx) revenue in Germany. The company now expects Rx revenue in Germany to reach EUR 730 to 760 million, up from the previously guided EUR 680 to 720 million. This represents growth of 45% to 51% for the year, compared to the earlier forecast of 35% to 43%. The upgrade was announced on September 28, 2026, and underscores the company's accelerating performance in the digital pharmacy sector.
Based on preliminary figures, Rx revenue in Germany grew by 51% year-on-year in September and 56% in the third quarter. September's strong performance came despite a high comparison base from the prior year when the current Rx bonus was introduced. The company will release its full third-quarter figures on October 29, 2026. This sustained growth is particularly significant as it demonstrates Redcare's ability to capitalize on the ongoing shift toward online prescription fulfillment, a trend that has been gaining traction across Europe.
"Our growth is backed by strong customer satisfaction: eRx NPS continues to rise, up 6 points year-on-year to 80 in August," said Olaf Heinrich, CEO of Redcare Pharmacy. The rising Net Promoter Score indicates that customers are not only adopting the service but also recommending it, which is critical for long-term retention and market expansion. While Rx revenue remained robust throughout the quarter, non-Rx revenue in Germany rebounded well in August and September after a softer July. This rebound suggests that the company's broader product portfolio remains resilient and can complement its prescription business.
The updated guidance for 2026 includes total revenue growth of 16% to 18%, up from the previous 15% to 17%. Non-Rx growth remains unchanged at 10% to 12%. The adjusted EBITDA margin is confirmed at between 2.5% and 3.0%, with the company benefiting from continued operating leverage. The flat quarter-on-quarter margin, despite significant revenue growth, highlights improving efficiency and scale in Redcare's operations.
These upward revisions matter because they signal the growing acceptance of digital pharmacies among patients and healthcare providers. As Europe's leading online pharmacy, Redcare Pharmacy operates in seven countries and serves over 14 million active customers. The strong Rx momentum in Germany, its largest market, could serve as a blueprint for further expansion in other regions. The company's ability to deliver prescription drugs safely and efficiently positions it at the forefront of the digital health transformation. For investors, the raised guidance reflects confidence in the business model and its ability to sustain growth even amid challenging macroeconomic conditions. The original release is available on www.newmediawire.com.
Looking ahead, Redcare Pharmacy will publish its Interim Statement for Q3 2026 and host a quarterly conference call on October 29, 2026. The company's Annual Report 2026 is scheduled for March 4, 2027. With two guidance raises already this year, Redcare Pharmacy is demonstrating that the digital pharmacy model is not just viable but thriving, with significant implications for the future of healthcare delivery in Europe.
